Existing local therapies for superficial transitional cell carcinoma (TCC) of the bladder have limited success in preventing progression to life-threatening, muscle-invasive disease, and novel therapies are needed. Recent studies have raised doubts concerning the feasibility of adenovirusmediated gene therapy for bladder cancer. We have therefore investigated adenoviral transduction of normal and malignant human urothelial cells, both as primary cultures and in intact epithelium. All 15 primary normal human urothelial cell lines tested were transduced in vitro by Adv-cmv-b-gal at high efficiency, and better than most human TCC cell lines. Eight primary human TCC explants were also successfully transduced. In contrast, in intact normal urothelium, transduction efficiency was lower, and occurred only in superficial epithelial layers. Expression of the hCAR adenovirus receptor, however, occurred throughout the full thickness of urothelium. Transduction of human TCC biopsy specimens was at least as efficient as intact normal urothelium. We demonstrate for the first time that adenoviral transduction of both normal and malignant human urothelial cells is feasible. A physical barrier, rather than hCAR status, may be the main determinant of transduction of intact epithelium. Clinical trials of adenovirus-mediated gene therapy for superficial bladder cancer are warranted.
Introduction
Bladder cancer is the fourth most common malignancy in males in Western society, and the 10th most common cause of cancer death. 1 One of the principal challenges in treating bladder cancer is to avoid progression of superficial tumours (Ta, T1 and Tis), to muscle-invasive disease (T2 and beyond), for which long-term survival is much poorer. 2 Despite post-operative administration of intra-vesical cytotoxic drugs and immunotherapy (eg Mycobacterium Bacille-Calmette-Guerin -BCG), approximately 25-30% of patients who present with superficial bladder tumours will progress to poorer prognosis, muscle-invasive disease. 3 Even with aggressive surgical intervention, 5-year survival in patients with muscle-invasive disease is no more than 50%. BCGrefractory superficial bladder tumours are therefore important targets for new treatments, as they represent potentially fatal tumours, without a currently accepted, effective therapy.
With increasing understanding of the molecular pathogenesis of bladder tumours, 4 gene therapy is an attractive option as a novel treatment strategy, designed to reduce the rate of progression of such tumours. Many superficial bladder tumours are relatively well differentiated and do not have a high rate of proliferation, and local delivery into the bladder should avoid the difficulties of systemic administration of viral gene therapy vectors. Hence, intra-vesical gene therapy using recombinant adenovirus vectors is an attractive approach.
In rodents, administration of adenoviruses to urothelium of both bladder and ureter has been shown to be feasible and safe. [5] [6] [7] [8] [9] Studies of human transitional cell carcinoma (TCC) cell line xenografts in animal models have demonstrated that adenoviral infection of human urothelial tumour cell lines is possible. 10, 11 However, a recent study 12 has demonstrated variable rates of transduction of a variety of established human TCC cell lines by adenovirus in vitro, and that poorer rates of infection correlate with low levels of expression of the human coxsackie-adenovirus receptor (hCAR). Such findings raise questions about the feasibility of adenovirus-mediated gene therapy for bladder cancer.
We have used in vitro monolayer culture and ex vivo fresh tissue explant and organ culture models to assess whether normal and tumour cells from human urothelial clinical specimens can be successfully transduced by a replication-defective adenovirus carrying the b-galactosidase marker gene (Adv-cmv-b-gal).
Results

Adenoviral transduction of normal human urothelial cells in vitro
We have investigated transduction by Adv-cmv-b-gal of a panel of primary monolayer cultures derived from normal human ureters. b-Galactosidase expression was first observable at around 6 h after a 30 min incubation with adenovirus, and was maximal at 24 h (data not shown). High efficiency was obtained in almost all cases (Table 1) . Efficiency of transduction of normal human urothelial (NHU) cells was comparable to that obtained with the human small cell carcinoma cell line A549, which is known to express hCAR at high levels 13 and at only an order of magnitude less than the human embryonic kidney cell line 293 (Figure 1) . At a multiplicity of infection (MOI) of 10, effectively 100% of NHU cells expressed bgalactosidase (Figure 2a) in all 15 primary lines tested. In contrast, only one of the six human TCC established cell lines achieved a transduction efficiency greater than 50% at an MOI of 10 (Table 1) with transduction efficiency of o10% in the established human bladder tumour cell line T24 (Figure 2c) . Quantitation of the percentage of normal and TCC cell line cells expressing virally encoded product was confirmed by FACS analysis of Ad-GFP-infected cells (data not shown). Transduction efficiency in NHUs was independent of passage number, with no obvious decrease in infectivity with time in culture, up to almost 4 weeks after commencement of primary culture ( Figure 2b and Table 1 ).
Adenoviral transduction of intact normal human urothelium ex vivo
The finding that monolayer cultures of NHUs can be transduced readily in vitro by adenoviruses with greater efficiency than established human TCC cell lines raises the possibility that the variability observed in transduction efficiency of TCC cell lines merely reflects adaptation of these cell lines to prolonged culture, and that adenoviral transduction of both normal and malignant cells in vivo might be easier than is suggested by the results of Li et al. 12 We therefore investigated the efficiency of transduction of intact human urotheliumboth as fresh ureteric specimens and in an organ culture model. This method also provides the opportunity to assess the depth of penetration of virus into the stratified epithelium of the urinary tract.
Immersion of freshly resected specimens of intact normal ureter in an Adv-cmv-b-gal suspension at the same concentration as that used for transduction of monolayer cultures, resulted in transduction of the most superficial layers of the urothelium only (Figure 3a) . There was no obvious time dependence of viral exposure, with similar results after immersing the pieces of intact ureter in viral suspension for 30 min to 24 h (data not shown). The addition of Adv-cmv-b-gal to the luminal surface of organ cultures also resulted in successful transduction of a proportion of the epithelial cells in the most superficial levels (Figure 3b ). In both fresh ureter and organ cultures, efficiency was lower than that seen in the NHU monolayer cultures, despite immersion of fresh ureter in an identical concentration of virus, and topical administration of a viral solution 200 times more concentrated to the organ cultures. To exclude the possibility that this lower efficiency might Table 1 ) is compared with various human bladder (EJ and VMCUB-3) and non-bladder (HeLa, cervical carcinoma; A549, lung carcinoma; 293, human embryonic kidney) established cell lines. TCC lines which can be seen by light microscopy to be transduced at efficiencies below approximately 10% (eg VMCUB-3, Table 1 ) do not show as detectably blue on the macroscopic scale shown here.
Adenovirus-mediated gene therapy for bladder cance JD Chester Adenovirus-mediated gene therapy for bladder cancer JD Chester be due to expression of hCAR only in superficial epithelial cells, immunohistochemistry was performed, using the anti-hCAR murine monoclonal antibody RmcB. 14 We observed homogeneous expression of hCAR throughout the full thickness of normal human ureteric epithelium (Figure 3e and f).
We have investigated the possibility that a physical barrier, such as the urothelial 'asymmetric unit membrane' (AUM), the presence of proteoglycan coating, or epithelial cell-cell contacts might limit adenoviral entry to the most superficial cells of the epithelium. We repeated the exposure of organ cultures to Adv-cmv-bgal, but following pretreatment using 0.1% EDTA solution 7 0.25% trypsin (Figure 3c and d). Pretreatment with EDTA clearly decreased the degree of cell surface contact between urothelial cells within the epithelium (Figure 3c ), but b-galactosidase expression was still confined to superficial layers of the urothelium. Pretreatment with both EDTA and trypsin produced a small improvement in efficiency, but no deeper penetration ( Figure 3d ). Similarly, pretreatment with 30% ethanol, which has been reported to improve transduction in murine bladders in vivo, 15 did not affect transduction efficiency of human urothelial organ cultures (data not shown).
Adenoviral transduction of human TCC bladder tumours
Having demonstrated that NHUs in monolayer culture and superficial layers of human urothelium can be readily transduced by replication-defective adenovirus, we assessed whether neoplastic human urothelial cells can also be transduced. Using primary explant cultures derived from eight fresh human TCC biopsy specimens, transduction efficiencies similar to those seen for NHUs in monolayer culture were obtained after several days in culture (Figure 4a and b and Table 2 ). In four of these eight cases, close to 100% of cells were transduced, at an MOI of 10.
We also investigated whether fresh papillary TCC ''cold-cup'' biopsy specimens could be infected with adenovirus, immediately after resection from the patient. Tumour biopsy fragments from three different patients were exposed, without disaggregation, to adenovirus, within 24 h after resection. In all three cases, dense blue staining was observed (Figure 4c ). Light microscopy of paraffin-embedded sections suggested that, as in fresh intact ureter and in organ cultures, adenoviral transduction is confined to the superficial layers of epithelial cells. The efficiency of transduction of these superficial cells was notably less than the near-100% levels in the monolayer cultures and, as in the intact urothelium in Figure 3 , predominantly involved superficial tumour cells (Figure 4d) . However, the efficiency appears to be no less than that seen in intact normal epithelium, despite a 200-fold lower concentration of virus.
Discussion
We have demonstrated that primary cultures of both normal and malignant human urothelial cells, derived from fresh clinical specimens, can be transduced by replication-defective adenovirus at moderate titres (MOI¼10). This represents the first demonstration of adenoviral transduction of normal and malignant urothelial cells from clinical specimens, though adenoviral infection of urothelial cells has previously been demonstrated in a variety of animal models, [5] [6] [7] [8] [9] and in animal xenografts using immortalized human TCC lines. 10, 11 The efficiency of transduction of monolayer cultures of Table 2 ), disaggregated and plated on plastic petri dishes, cultured for 3-5 days before exposure to Adv-cmv-b-gal (same concentration of virus as used for MOI¼10 infection of NHUs in Figures 1 and 2 ) and then stained 24 h later for b-galactosidase expression. In some colonies, there is an absence of blue staining at the centre, due to incomplete coverage of the tissue fragment by the thin layer of viral suspension applied. (b) Staining for b-galactosidase expression in cells grown out from a particularly large fragment of bladder tumour after 7 days in culture (different patient, iii in Table 2 , to that in (a)). (c) Adenoviral transduction of freshly explanted intact human TCC bladder tumour. A cold-cup resection clinical specimen was immersed in Adv-cmvb-gal virus-containing solution (same concentration as for NHU and TCC primary cultures and 200-fold lower than for organ cultures) for 30 min at 371C, then cultured overnight before staining for b-galactosidase expression, and wax embedding. Note that there is a greater efficiency than for organ cultures of intact urothelium, despite much lower viral concentration. As in intact urothelium, only superficial layers are infected. 
The ease of transduction of monolayer cultures of NHUs and of primary cultures of TCCs with adenovirus implies that therapeutic use of adenoviral vectors for gene therapy of superficial bladder cancer may be less difficult than has been previously suggested. However, it must be borne in mind that the urothelium is a multilayered structure with a natural barrier function. Our experiments on intact epithelium, in the form of both fresh ureter and organ cultures, show that cells in the intact urothelium are less efficiently transduced than cells cultured as monolayers, even at titres of virus up to two orders of magnitude greater than those required to infect 100% of monolayer cells, and transduction occurs only in a proportion of cells in the more superficial layers of the epithelium. There remain, therefore, significant obstacles to intra-vesical gene therapy for bladder cancer.
Several factors may account for the very high transduction efficiency in NHUs and variable expression of the reporter gene through intact urothelium. Possible explanations for the latter result include failure of virus to enter cells due to lack of cell surface receptors, failure of viral penetration to deeper layers, or lack of expression of the transgene after cell entry. Differential expression of hCAR in various layers of stratified epithelium may explain the restriction of adenoviral transduction to superficial layers. Qualitatively similar results to those we have obtained in human urothelium have recently been published for human oropharyngeal epithelium. 16 High-hCAR-expressing, undifferentiated cells in basal layers of the stratified oropharyngeal epithelium were thought to be shielded from adenovirus by overlying layers of hCAR-poor squamous epithelial cells. Expression of hCAR might, therefore, be seen as being the key determinant of adenoviral transduction, because of the paucity of hCAR expression in more superficial layers of the epithelium. However, our immuno-histochemistry results using a monoclonal antibody against hCAR show homogeneous expression of the receptor throughout the full thickness of urothelium, implying that, in urothelium at least, hCAR status alone is insufficient explanation for the observed distribution of viral gene expression. This is supported by the fact that normal urothelial organ cultures were derived from the same pieces of tissue, from the same patients, as the NHU monolayer cultures, which are transduced much more efficiently.
An alternative explanation for the difference in transduction seen here between normal urothelial cells in monolayer and in intact epithelium is that fully differentiated urothelium might present a physical barrier to viral penetration. It has been suggested 17 that a physical barrier, such as the unique structure of the urothelial 'asymmetric unit membrane' or a mucopolysaccharide/glycosaminoglycan layer, might explain the low efficiency and superficial distribution of transduction by adenovirus also seen in orthotopic human TCC grafts in rodent bladders.
Possible solutions to overcoming such a physical barrier have been investigated in previous studies in rodent models which demonstrated that the efficiency of transduction of bladder epithelium is improved by pretreatment with 30% ethanol, 15 with polyamides 18 or other organic substances. 19 Although we have not been able to replicate some of these observations in human urothelial organ cultures, it will be interesting to investigate the effect of treating our organ culture specimens with other chemical agents. Other physical barriers, such as the presence of tight junctions between the cells of intact urothelium or the baso-lateral subcellular localization of hCAR seen in airway epithelia 20 may hinder adenoviral entry. However, the lack of a significant alteration in transduction efficiency following EDTA and trypsin pretreatment shown here may argue against this. Further studies are needed to establish whether the use of organic substances can improve the efficiency of transduction of intact human urothelium, as well as in animal models, and that incomplete bgalactosidase staining is indeed due to a failure of viral penetration, rather than inability to express the transgene.
Our observation that all the tumour biopsies we have tested can be successfully transduced by adenovirus is in keeping with data recently published by Loskog et al, 21 showing that all 27 bladder tumour specimens examined showed detectable levels of expression of hCAR by immunohistochemistry, with hCAR expression being higher in superficial than in muscle-invasive tumours. Our results showing that the efficiency of transduction of freshly biopsied human TCC specimens is at least as high as in intact urothelium, despite a much lower concentration of virus, suggests a degree of tumour selectivity, possibly because of disruption of a physical barrier in tumours. These results suggest that gene therapy for superficial (Ta, T1 and Tis) bladder cancers, employing intra-vesical delivery of replication-defective adenoviral vectors, will be feasible, and that hCAR expression need not be a limiting factor. Indeed, Kuball et al have recently published a Phase I trial of intra-vesical administration of Ad-p53. 22 Nevertheless, efficient transduction of intact urothelium, particularly its deeper layers (and, hence, deeper muscle-invasive tumours) remains a potential obstacle to successful clinical trials and may require novel approaches. These might include the use of novel recombinant viral vectors designed to enhance cell kill via bystander effects. 23, 24 Organ cultures may provide a useful model for assessing the utility of such gene therapy Another approach to extending adenoviral infection beyond superficial layers of the urothelium might be to employ selectively replication-competent, rather than replication-defective, viral vectors. In this way, infection of superficial layers would result in a productive infection, and subsequent rounds of viral replication might then spread a therapeutic gene to deeper epithelial layers. An optimal therapeutic index for oncolytic viral gene therapy for bladder cancer will require a degree of tumour-selective replication of the viral vector. To achieve this, one might exploit the known molecular pathogenesis of bladder tumours. A large proportion of human bladder tumours are defective for expression of the tumour suppressor genes p53 and pRb. 4 The use of selectively replicating adenoviral vectors which possess mutations in E1B 25, 26 or E1A 27,28 regions of the adenoviral genome, and which are thereby potentially able to selectively kill tumours with defects in p53 or pRb pathways may therefore provide a gene therapy strategy for bladder cancer with a highly favourable therapeutic index. On this basis, we have obtained approval for a Phase I clinical trial of the selectively replicating adenovirus ONYX-015 25 in patients with high-risk superficial bladder cancer.
Materials and methods
Culture methods
Normal human urothelial cells were cultured from surgical specimens of ureter and renal pelvis, essentially according to the method of Hutton et al. 29 Harvested tissues were immediately placed in ''Transport Medium'' (Hanks' balanced salt solution (HBSS) with Ca 2+ and Mg 2+ , 10 mM HEPES pH 7.6 and 20 kallikrein-inhibiting units/ml (KIU/ml) aprotinin), stored briefly at 41C and processed within 24 h of resection. The outer surface of the specimen was freed from loose connective tissue, ureters opened longitudinally, and the specimen incubated, urothelial side downwards, in ''Stripper Medium'' (HBSS without Ca 2+ and Mg
2+
, 0.1% EDTA, 10 mM HEPES pH 7.6 and 20 KIU/ml aprotinin) overnight at 41C. The urothelial sheets were then gently freed from the underlying stroma using sterile forceps, collected and centrifuged at 180g for 5 min. The urothelial cells were resuspended in 200 U/ml collagenase IV and incubated at 371C for 20 min. Cells were pipetted up and down to give a single-cell suspension, washed and finally resuspended in NHU Growth Medium (keratinocyte serum-free medium supplemented with bovine pituitary extract and recombinant epidermal growth factor, which were added according to the manufacturer's instructions to give final concentrations of 50 mg/ml and 5 ng/ml, respectively; cholera toxin was included at 30 ng/ml). NHU cells were seeded at a minimum plating density of 4 Â 10 4 cells/cm 2 in tissue culture dishes for transduction with adenovirus on the following day. The remainder were grown in tissue culture flasks (Primaria, Becton Dickinson). Cultures were harvested near to confluence by treatment with 0.1% EDTA/PBS for 3 min at 371C, followed by a further 3 min at 371C with 0.25% trypsin in 0.1% EDTA/PBS. Detached cells were resuspended in NHU Growth Medium containing 1.5 mg/ml soybean trypsin inhibitor (Sigma), collected by centrifugation, washed in NHU Growth Medium and re-seeded at a split ratio of 1:3 to 1:6. NHU cells grown in this way routinely require 4-7 days to return to confluence and can be routinely passaged between six and eight times, without loss of viability.
Primary cultures of human transitional cell carcinoma (TCC) were grown from biopsy specimens taken at cystoscopy. Some tumours were used for immediate (o24 h) adenoviral transduction. Others were used to initiate explant cultures, essentially according to the method of Reznikoff et al, 30, 31 prior to transduction by adenovirus. Briefly, fresh biopsy specimens placed in Transport Medium were minced using a sterile scalpel in a glass Petri dish, collected by centrifugation, resuspended in ''TCC Growth Medium'' (Ham's F12 medium, 1% foetal bovine serum, 5 Â 10 À8 M sodium selenite, 10 À4 M ethanolamine, 2.7 mg/ml D-(+)-glucose, 2 mM Lglutamine, 10
À4
M non-essential amino acids, 10 mg/ml insulin, 5 mg/ml transferrin, 1 mg/ml hydrocortisone, 100 U/ml penicillin, 100 mg/ml streptomycin) and plated in 3.5 cm tissue culture dishes. Cells were transduced with adenovirus 3-5 days after the initiation of culture. Passaging was not attempted.
Established human tumour cell lines (TCC cell lines T24, RT4, UMUC-3, RT112, EJ and VMCUB-3; small cell lung cancer cell line A549; cervical carcinoma cell line HeLa; and human embryonic kidney cell line 293 transformed with sheared adenoviral DNA) were grown in monolayer culture according to standard protocols.
Intact urothelium was obtained from off-cuts of normal ureter from nephro-ureterectomy specimens. Excess connective tissue was removed from the outer suface of the ureter before opening the ureter longitudinally, and cutting into pieces of approximately 5 Â 5 mm using a sterile scalpel. These fresh ureteric specimens were either used immediately for viral transduction or maintained in organ culture prior to treatment with virus. Organ culture of intact human urothelium is a well-established technique, 32, 33 and was performed essentially according to the method of Scriven et al. 34 Urothelial tissue specimens were cultured at an air-liquid interface on 25 mm tissue culture inserts (Falcon) supported in six-well plates containing 'Organ Culture Medium' (Waymouth's medium supplemented with 10% foetal bovine serum, 0.45 mg/ml ferrous sulphate, 2 mg/ml hydrocortisone hemisuccinate and 300 mg/ml vitamin C). Cultures were maintained for 7-10 days prior to the addition of adenovirus.
All cultures were incubated at 371C in a humidified atmosphere containing 5% carbon dioxide.
Adenoviral transduction
Prior to use, adenovirus was titrated by cytopathic effect end-point dilution method 35 to establish the number of functional particles (plaque-forming units (pfu)/ml). All multiplicities of infection (MOI) are stated in terms of pfu/cell. Adv-cmv-b-gal, 36 a replication-defective human type 5 adenovirus (Ad5) containing the b-galactosidase gene linked to an internal CMV-IE promoter and followed by an SV40 polyadenylation [p(A)] signal, inserted into the deleted E1 region of the viral genome (3.8 Â 10 12 viral particles/ml; 2.2 Â 10 9 pfu/ml) was obtained from Introgen Therapeutics Inc., Houston, TX, Adenovirus-mediated gene therapy for bladder cance JD Chester USA. The virus does not contain a nuclear localizing signal.
NHU cells were transduced with adenovirus at various passages, including the first plating (designated as passage 1, P1). For adenoviral transduction of NHU and established tumour cell lines, cells were plated in six-well plates at a density of 2 Â 10 5 cells/well in 2 ml of appropriate growth medium and grown for 24 h. Medium was aspirated and cells washed with fresh medium which was then replaced with 0.2 ml of medium containing adenovirus at various dilutions (MOI 10, 1, 0.1 and 0.01). Cells were incubated with virus at 371C for 30 min. Adenovirus-containing medium was aspirated, the cells washed and then 2 ml fresh medium added. Cells were then cultured overnight, fixed the next morning, then stained for b-galactosidase activity, as below.
Primary explant cultures of cold-cup biopsy specimens from human bladder TCC tumours were disaggregated using a scalpel, cultured in 3.5 cm dishes and treated with 0.2 ml of adenovirus suspension 3-5 days after plating, exactly as above. The concentration of virus used was the same as for the infection of NHU and established tumour cell lines (MOI¼10). However, the smaller number of cells in culture results in a higher effective MOI. Cells were incubated overnight before fixation and staining for b-galactosidase activity, as for NHUs above.
Some human TCC tumour biopsy specimens were treated directly with adenovirus, without disaggregation. Tumour biopsy fragments preserved in Transport Medium were immersed in 1 ml of Organ Culture Medium containing 5 ml of viral stock solution (final concentration of adenovirus identical to that used for infecting monolayer cultures) and incubated for 30 min. The tumour was washed with virus-free medium and then resuspended in 1 ml fresh medium and incubated overnight prior to fixation and staining for b-galactosidase activity. Stained specimens were then embedded in paraffin wax for sectioning.
Fresh ureteric specimens were transduced by adenovirus by immersion in viral suspension, exactly as for the intact biopsy specimens above, again using a concentration of virus identical to that used for transduction of NHUs. For transduction of intact human urothelial organ cultures, 2 ml of undiluted adenoviral stock solution (ie 200 times more concentrated than that used to infect primary tumours and monolayer cultures) was applied to the uppermost (luminal, urothelial) surface, 7 days after the commencement of culture. Unlike monolayer cultures, the viral solution was not removed from organ cultures, but left in situ for 24 h prior to fixation and staining for b-galactosidase activity.
In experiments to investigate the effects of EDTA 7 trypsin on penetration of virus into the deeper layers of the epithelium, organ cultures were treated with EDTA 7 trypsin, immediately before treatment with virus. The medium was aspirated and the organ culture specimen, still on the well insert, was washed by immersion in PBS. The specimen was then incubated at 371C in 0.1% EDTA/PBS either for 6 min, or for 3 min followed by 3 min in 0.25% trypsin in 0.1% EDTA/PBS. The organ cultures were washed with fresh Organ Culture Medium, which was then aspirated and medium replaced below the insert membrane only, recreating the air/ liquid interface, prior to the addition of virus. Specimens were exposed to virus for 24 h, then fixed, stained for b-galactosidase expression and wax embedded, as below.
Assay for B-galactosidase activity
Twenty-four hours after the addition of adenovirus, monolayer cultures of NHUs, established human tumour cell lines and primary explant cultures of TCC were washed with 2 ml PBS, then incubated in 1 ml fixative (2% formaldehyde, 0.05% glutaraldehyde in PBS) for 5 min at room temperature. Fixed cells were washed twice with 2 ml PBS, then immersed in staining solution (1 mg/ml 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-gal), 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM MgCl 2 in PBS) for 2 h at 371C, washed with a further 2 ml PBS, then viewed under a light microscope.
Adenovirus-treated fresh TCC tumour biopsy specimens and intact organ cultures were fixed and stained in exactly the same way as above, except that specimens were incubated with staining solution overnight. Stained specimens were washed in PBS, prior to dehydration and paraffin wax embedding, according to standard histological procedures. Paraffin wax sections 5 mm in thickness were counter-stained with haematoxylin and eosin and viewed under a light microscope.
Double label indirect immunofluorescence
Segments of normal human ureter from nephrectomy specimens were snap-frozen in liquid nitrogen shortly after removal from the patient. Frozen sections were airdried and incubated with mouse anti-human CAR (a gift from J Bergelson, Children's Hospital of Philadelphia, PA, USA) and rabbit anti-laminin (ICN) antibodies for 60 min in a humidified atmosphere at ambient temperature. Sections were washed in PBS, fixed in methanol: acetone (1:1), air-dried and incubated for a further 30 min with goat anti-mouse Ig-FITC and goat antirabbit Ig TxRd antibody conjugates (Southern Biotechnology Associates). Tissues were washed in 0.25% Tween-20 in PBS followed by distilled water and airdried. Sections were mounted with Vectorshield (Vector Labs) and viewed under epifluorescent illumination using a Zeiss Axioplan microscope and a dual FITC/ TxRd filter.
